Emerging Targets for Oncology & Beyond
Discover. Multiplex. Advance. - Expanding the Target Landscape
5/11/2027 - May 12, 2027 ALL TIMES EDT
As the antigen landscape crowds around established targets, the question for every discovery team is what comes next. The Emerging Targets for Oncology & Beyond track aims to answer this question by examining how data-driven and computational approaches are widening the druggable target space, and how new strategies are bringing intracellular antigens within reach of antibody-based and cell-based therapies. It explores next-generation and re-emerging targets across solid tumors, hematologic malignancies, and the tumor microenvironment, and looks at target multiplexing, where multi-antigen designs and checkpoint-axis combinations are redefining how optimal pairings are chosen. For discovery and translational teams, this is where to find the target ideas and pairing logic that will shape the next generation of pipelines.
Preliminary Agenda

PLENARY KEYNOTE SESSION

Panel Moderator:

PANEL DISCUSSION: From Mechanism to Modality: Smarter Drug Design in Autoimmunity

Yang Shen, PhD, Executive Director, Antibody Engineering, Bispecifics, Regeneron , Vice President , Bispecifics & Antibody Engineering , Regeneron

Panelists:

Stephen J. Demarest, PhD, CSO, Tentarix Biotherapeutics , CSO , Tentarix

Ryan P. Larson, PhD, Vice President & Head, Translational Sciences, Umoja Biopharma , SVP & Head , Translational Sciences , Umoja Biopharma

Kira Rubtsova, PhD, Associate Vice President, Eli Lilly and Company , Dir , Eli Lilly & Co

Qizhi Tang, PhD, Professor in Residence, Surgery, University of California San Francisco , Prof in Residence , Surgery , Univ of California San Francisco

EXPANDING TARGET SPACE

A Multimodal Foundation Model of the Immune System Enables Development of Precise Target Product Profiles

Photo of Lisa Elizaveta Freinkman, PhD, SVP, Discovery, Epana Bio , SVP, Discovery , Discovery , Epana Bio
Lisa Elizaveta Freinkman, PhD, SVP, Discovery, Epana Bio , SVP, Discovery , Discovery , Epana Bio
Photo of Rebecca J Carlson, PhD, CoCEO, Deliverome Bio , Co CEO , Deliverome Bio
Rebecca J Carlson, PhD, CoCEO, Deliverome Bio , Co CEO , Deliverome Bio

Antibody and cell-based therapies achieve selectivity by binding cell-surface targets, but each modality requires different target properties: antibody–drug conjugates require internalization, whereas internalization reduces the efficacy of T cell engagers and CAR T cells. Without systematic data, over 80% of ADCs in development pursue the same 11 targets. The Deliverome Project is mapping surface abundance and internalization at-scale using proteomics and surface-protein ORF screens in primary cells and healthy human tissues, and openly releasing all results. We also built a freely available, gold-standard atlas of human cell-surface proteins using LLMs to analyze full-text scientific papers.

ESCAPING TARGET CROWDING: NEXT-GEN AND (RE)EMERGING TARGETS

KEYNOTE PRESENTATION: Leader Sequence-Derived Antigen as a Therapeutic Target in Acute Myeloid Leukemia

Photo of Gheath Alatrash, PhD, Professor, Medicine, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center , Prof, Medicine , Stem Cell Transplantation and Cellular Therapy , MD Anderson Cancer Ctr
Gheath Alatrash, PhD, Professor, Medicine, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center , Prof, Medicine , Stem Cell Transplantation and Cellular Therapy , MD Anderson Cancer Ctr

Successful immunotherapy depends on identifying tumor-associated antigens that are effectively presented to the immune system. This work highlights the importance of considering not only protein expression, but also protein localization and trafficking, in selecting optimal therapeutic targets. Using cathepsin G (CG) in acute myeloid leukemia (AML) as a model, we demonstrate how intracellular and extracellular protein pools contribute to antigen processing and presentation. These insights enabled the development of CG1-directed immunotherapies, including TCR-mimic constructs, bispecific antibodies, and CAR T cells. Preclinical studies showed potent antitumor activity, supporting clinical translation and expanding opportunities for precision immunotherapy across malignancies.

Targeting GDF-15 with Visugromab: Unlocking Antitumor Immunity and Relieving Cancer Cachexia

Photo of Stefan Ries, PhD, CSO, CatalYm , CSO , CatalYm
Stefan Ries, PhD, CSO, CatalYm , CSO , CatalYm
Photo of Amy Erbe-Gurel, PhD, Research Assistant Professor, Hematology, Oncology, Transplant & Cellular Therapy, University of Wisconsin–Madison , Research Asst Prof , Hematology & Oncology & Transplant & Cellular Ther , Univ of Wisconsin Madison
Amy Erbe-Gurel, PhD, Research Assistant Professor, Hematology, Oncology, Transplant & Cellular Therapy, University of Wisconsin–Madison , Research Asst Prof , Hematology & Oncology & Transplant & Cellular Ther , Univ of Wisconsin Madison
Photo of Monica Gostissa, PhD, CSO, Matrisome Bio , CSO , Matrisome Bio
Monica Gostissa, PhD, CSO, Matrisome Bio , CSO , Matrisome Bio
Photo of Victor S. Goldmacher, PhD, CSO, Research & Development, ImmuVia , CSO , R&D , ImmuVia, Inc.
Victor S. Goldmacher, PhD, CSO, Research & Development, ImmuVia , CSO , R&D , ImmuVia, Inc.

IMV-M, a MUC16 × DR5 bispecific antibody, has demonstrated strong antitumor activity in multiple CDX and PDX xenograft models of ovarian cancer, pancreatic cancer, and non-small cell lung cancer. It has also demonstrated preclinical synergy with daraxonrasib, a recently FDA-approved RAS inhibitor for pancreatic cancer. The program is advancing through preclinical development and chemistry, manufacturing, and controls (CMC) activities.

TARGET MULTIPLEXING: SELECTING THE OPTIMAL TARGET PAIRING

Ivonescimab: A Novel First-in-Class PD-1 x VEGF Bispecific Antibody

Photo of Pipat Piewngam, PhD, Senior Principal Scientist, Inflammation & Oncology, Summit Therapeutics Inc. , Sr Principal Scientist , Inflammation & Oncology , Summit Therapeutics Inc
Pipat Piewngam, PhD, Senior Principal Scientist, Inflammation & Oncology, Summit Therapeutics Inc. , Sr Principal Scientist , Inflammation & Oncology , Summit Therapeutics Inc
Photo of Hadas Reuveni, PhD, Vice President, Research & Development Purple Biotech Ltd. , VP R&D , R&D , Purple Biotech Ltd
Hadas Reuveni, PhD, Vice President, Research & Development Purple Biotech Ltd. , VP R&D , R&D , Purple Biotech Ltd

Victor Sun, PhD, Senior Principal Scientist, Sanofi , ED, Head of Antibody Discovery and Engineering , Antibody Discovery and Protein Engineering , Innovent Bio

BCMA is highly expressed on multiple myeloma cells, while GPRC5D is almost exclusively expressed on MM cells. These features make these two antigens ideal targets for or-gated targeting of multiple myeloma. Innovents IBI3003, a T cell engager targeting both GPRC5D and BCMA, may cover the largest potential population of patients, achieve better efficacy, and overcome the resistance to BCMA/CD3 or GPRC5D/CD3 as single agent.

EMERGING STRATEGIES FOR TARGETING INTRACELLULAR CANCER ANTIGENS

Overcoming Low pMHC Target Density in Solid Tumors through Multi-pMHC Targeting

Photo of Jack Silberstein, PhD, Founder & CEO, Deck Bio , Founder & CEO , Deck Bio
Jack Silberstein, PhD, Founder & CEO, Deck Bio , Founder & CEO , Deck Bio
Photo of Lauren Stopfer, PhD, Executive Director, Proteomics & Innovation, Aethon Therapeutics , Exec Dir Biology & Innovation , Preclinical Biology , Aethon Therapeutics
Lauren Stopfer, PhD, Executive Director, Proteomics & Innovation, Aethon Therapeutics , Exec Dir Biology & Innovation , Preclinical Biology , Aethon Therapeutics
Photo of Garrett Rappazzo, PhD, Scientist, Platform Technologies, Adimab , Senior Scientist , Platform Technologies , Adimab LLC
Garrett Rappazzo, PhD, Scientist, Platform Technologies, Adimab , Senior Scientist , Platform Technologies , Adimab LLC

Peptide-MHC (pMHC)-targeting therapeutics can potently eradicate diseased cells, but require exquisite specificity to prevent off-target reactivity with structurally similar peptides presented by healthy cells. Conventional specificity screens sacrifice either throughput or resolution to identify leads and characterize off-target risks. We present a switchable yeast-based pMHC library platform that enriches and differentiates highly specific binders in high throughput, and defines their off-target risks with high resolution via ML-enabled predictions.


For more details on the conference, please contact:
Mimi Langley
Executive Director, Conferences
Cambridge Healthtech Institute
Email: [email protected]

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Email: [email protected]

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-1340
Email: [email protected]


Register

View By:


Premier Sponsors

Biointron_new       Kactus